NovaBay Pharmaceuticals Inc - Asset Resilience Ratio
NovaBay Pharmaceuticals Inc (NBY) has an Asset Resilience Ratio of 66.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how NovaBay Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check NovaBay Pharmaceuticals Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down NovaBay Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NovaBay Pharmaceuticals Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $2.31 Million | 66.22% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $2.31 Million | 66.22% |
Asset Resilience Insights
- Very High Liquidity: NovaBay Pharmaceuticals Inc maintains exceptional liquid asset reserves at 66.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
NovaBay Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare NovaBay Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Jinyu Bio-Technology Co Ltd
SHG:600201 |
Biotechnology | 1.20% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for NovaBay Pharmaceuticals Inc (2005–2024)
The table below shows the annual Asset Resilience Ratio data for NovaBay Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.56% | $430.00K | $3.42 Million | -22.08pp |
| 2023-12-31 | 34.65% | $3.13 Million | $9.03 Million | +1.95pp |
| 2022-12-31 | 32.70% | $5.36 Million | $16.40 Million | +1.40pp |
| 2021-12-31 | 31.30% | $7.50 Million | $23.98 Million | -47.14pp |
| 2020-12-31 | 78.44% | $11.95 Million | $15.24 Million | +16.61pp |
| 2019-12-31 | 61.83% | $6.94 Million | $11.22 Million | +27.82pp |
| 2018-12-31 | 34.00% | $3.18 Million | $9.36 Million | +2.26pp |
| 2017-12-31 | 31.74% | $3.20 Million | $10.08 Million | -30.10pp |
| 2016-12-31 | 61.84% | $9.51 Million | $15.38 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $5.08 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $7.54 Million | -- |
| 2013-12-31 | 16.31% | $2.55 Million | $15.65 Million | -5.18pp |
| 2012-12-31 | 21.50% | $4.13 Million | $19.23 Million | -14.27pp |
| 2011-12-31 | 35.77% | $5.71 Million | $15.96 Million | +27.57pp |
| 2010-12-31 | 8.20% | $1.27 Million | $15.52 Million | +6.49pp |
| 2009-12-31 | 1.71% | $300.00K | $17.52 Million | -45.99pp |
| 2007-12-31 | 47.71% | $11.41 Million | $23.92 Million | -4.40pp |
| 2006-12-31 | 52.11% | $6.18 Million | $11.87 Million | +23.92pp |
| 2005-12-31 | 28.19% | $1.00 Million | $3.56 Million | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more